Crystalline insulin-conjugates

A conjugate and insulin technology, applied in the direction of insulin, carrier binding/immobilization peptide, hormone peptide, etc.

Inactive Publication Date: 2012-02-01
SMARTCELLS
View PDF34 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, plant lectins are known to be particularly immunogenic, eliciting the production of high titers of anti-lectin-specific antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline insulin-conjugates
  • Crystalline insulin-conjugates
  • Crystalline insulin-conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0412] Example 1 - Synthesis of Azidoethyl Glucose (AzEG)

[0413] a. Synthesis of bromoethylglucose

[0414] DOWEX 50Wx4 resin (Alfa Aesar, Ward Hill, MA) was washed with deionized water to remove color. 225 g of D-glucose (1.25 mol; 1 equiv, Alfa Aesar) and 140 Gram the mixture of DOWEX 50Wx4 and heat the stirred mixture to 80°C for 4 hours. The reaction was monitored by TLC (20% methanol / dichloromethane (DCM)). After about 4 hours, the reaction was complete and it was cooled to room temperature. The solution was filtered to remove the resin, and the resin was washed with ethyl acetate and DCM. The resulting filtrate was stripped to an amber oil in a rotary evaporator. A total of 400 g was obtained after evaporation.

[0415] The amber oil was purified on silica gel (4 kg silica packaged in DCM) in the manner described below. The crude product was dissolved in DCM and loaded onto the column, then eluted with 2 x 4L 10% methanol / DCM, 2 x 4L 15% methanol / DCM and 3 x 4L ...

Embodiment 2

[0421] Example 2 - Synthesis of Azidoethylmannose (AzEM)

[0422] a. Synthesis of bromoethylmannose

[0423] DOWEX 50Wx4 resin (Alfa Aesar, Ward Hill, MA) was washed with deionized water to remove color. 225 g of D-mannose (1.25 mol; 1 eq, Alfa Aesar) and A mixture of 140 grams of DOWEX 50Wx4 was added and the stirred mixture was heated to 80°C for 4 hours. The reaction was monitored by TLC (20% methanol / dichloromethane (DCM)). After about 4 hours, the reaction was complete and then cooled to room temperature. The solution was filtered to remove the resin, and the resin was washed with ethyl acetate and DCM. The resulting filtrate was evaporated in a rotary evaporator to an amber oil.

[0424] The amber oil was purified on silica gel (4 kg silica packaged in DCM) in the manner described below. The crude product was dissolved in DCM and loaded onto the column, then eluted with 2 x 4L 10% methanol / DCM, 2 x 4L 15% methanol / DCM, and 3 x 4L 20% methanol / DCM. Fractions contai...

Embodiment 3

[0430] Example 3 - Synthesis of Azidoethylmannobiose (AzEBM)

[0431] The AzEM compound from Example 2 was selectively protected using xylylene ether, purified by column chromatography, and subsequently reacted with benzyl bromide to afford 1-α-(2-azidoethyl)-4,6- Benzaldehyde Diacetal-3-Benzyl-Mannopyranoside. Subsequent glycosylation of the product with 1-α-bromo-2,3,4,6-tetrabenzoylmannopyranoside under strictly anhydrous conditions using silver trifluoromethanesulfonate chemistry yielded the Protected - azidoethylmannobiose product. The intermediate is then deprotected to remove the benzoyl group to give AzEBM.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides crystalline insulin-conjugates. The present disclosure also provides formulations, methods of treatment, methods of administering, and methods of making that encompass these crystalline insulin-conjugates.

Description

[0001] related application [0002] This application claims U.S. Provisional Application No. 61 / 147,878, filed January 28, 2009, U.S. Provisional Application No. 61 / 159,643, filed March 12, 2009, U.S. Provisional Application No. 61 / 162,107, filed March 20, 2009 , U.S. Provisional Application No. 61 / 163,084, filed March 25, 2009, U.S. Provisional Application No. 61 / 219,896, filed June 24, 2009, U.S. Provisional Application No. 61 / 219,897, filed June 24, 2009, 2009 Priority to U.S. Provisional Application No. 61 / 223,572, filed July 7, 2009, and U.S. Provisional Application No. 61 / 252,857, filed October 19, 2009, the contents of each of which are hereby incorporated by reference in their entirety. Background technique [0003] Most "controlled release" drug delivery systems known in the art (e.g., U.S. Pat. The amount (eg, metabolite) is proportional to the interval and concentration at which the drug is delivered to the patient. The drug in these prior art systems is thus not ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/62A61K38/28
CPCC07K14/62A61K38/28A61K47/48092A61K47/549A61P3/10C07K17/10A61K47/26
InventorT.C.锡安T.M.兰卡斯特
OwnerSMARTCELLS